Drug Profile

Rilzabrutinib - Principia Biopharma

Alternative Names: PRN 1008; SAR-444671; Wayrilz

Latest Information Update: 11 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Principia Biopharma
Developer Principia Biopharma; Sanofi
Class 2 ring heterocyclic compounds; Amines; Anti-inflammatories; Antianaemics; Antiasthmatics; Eye disorder therapies; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Autoimmune haemolytic anaemia; Immunoglobulin G4-related disease; Idiopathic thrombocytopenic purpura; Sickle cell anaemia; Pemphigus; Pemphigus vulgaris
New Molecular Entity Yes

Marketed Idiopathic thrombocytopenic purpura
Phase III Autoimmune haemolytic anaemia; Immunoglobulin G4-related disease; Sickle cell anaemia
Phase II Asthma; Chronic urticaria; Focal segmental glomerulosclerosis; Graves' disease; Lipoid nephrosis
No development reported Liver disorders
Discontinued Atopic dermatitis; Pemphigus; Pemphigus vulgaris

02 Mar 2026 Rilzabrutinib - Principia Biopharma receives Orphan Drug status for Immunoglobulin G4 related disease in Japan
09 Feb 2026 Rilzabrutinib - Principia Biopharma receives Breakthrough Therapy status for Autoimmune haemolytic anaemia in USA
09 Feb 2026 Rilzabrutinib - Principia Biopharma receives Orphan Drug status for Autoimmune haemolytic anaemia in European Union

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com